|
Title
|
|
|
|
Phase
|
|
|
|
Protocol IDs
|
|
|
|
Aromatase Inhibitor Clinical Trial
|
|
|
|
Phase IV
|
|
|
|
0412-14
UO1-GM61373-06, NCT00228956
|
|
|
Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer
|
|
|
|
Phase IV
|
|
|
|
0501-37
NCT00352872
|
|
|
Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-Menopausal Women With Breast Cancer
|
|
|
|
Phase IV
|
|
|
|
CFEM345DUS59
NCT00688909
|
|
|
Using the ContureĀ® Multi-Lumen Balloon to Deliver Accelerated Partial Breast Brachytherapy
|
|
|
|
Phase IV
|
|
|
|
SENORX-S07-002
NCT00699101
|
|
|
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
|
|
|
Phase III, Phase II
|
|
|
|
20050113
NCT00243685
|
|
|
Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer
|
|
|
|
Phase III, Phase II
|
|
|
|
WHC-MRI-GU-2006-097
NCT00397761
|
|
|
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer
|
|
|
|
Phase III, Phase II
|
|
|
|
0120070323
NCT00698971
|
|
|
Letrozole After Tamoxifen in Treating Women With Breast Cancer
|
|
|
|
Phase III
|
|
|
|
CAN-NCIC-MA17
CALGB-49805, E-JMA17, EORTC-10983, IBCSG-BIG97-01, NCCTG-JMA17, SWOG-JMA17, JRF-Vor-Int-10, NCCTG-CAN-MA17, SWOG-CAN-MA17, NCT00003140, JMA17, MA17
|
|
|
Combination Chemotherapy in Treating Women With Breast Cancer
|
|
|
|
Phase III
|
|
|
|
CALGB-40101
CALGB-40101, NCT00041119
|
|
|
Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
|
|
|
|
Phase III
|
|
|
|
IBCSG-2402
BIG-2-02, CALGB-IBCSG-2402, CAN-NCIC-IBCSG-2402, NCCTG-IBCSG-2402, NSABP-IBCSG-2402, SWOG-IBCSG-2402, NABCI-IBCSG-2402, UCLA-0403024-01, EU-20334, IBCSG-24-02, NCT00066690, EUDRACT-2004-000166-13
|
|